These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

969 related articles for article (PubMed ID: 26976796)

  • 21. Beneficial Effects of the Peroxisome Proliferator-Activated Receptor α/γ Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension.
    Tsai HC; Li TH; Huang CC; Huang SF; Liu RS; Yang YY; Hsieh YC; Lee KC; Huang YH; Hou MC; Lin HC
    Am J Pathol; 2018 Jul; 188(7):1608-1624. PubMed ID: 29929914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of paeoniflorin on tumor necrosis factor-α-induced insulin resistance and changes of adipokines in 3T3-L1 adipocytes.
    Kong P; Chi R; Zhang L; Wang N; Lu Y
    Fitoterapia; 2013 Dec; 91():44-50. PubMed ID: 23978582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
    Henry RR; Lincoff AM; Mudaliar S; Rabbia M; Chognot C; Herz M
    Lancet; 2009 Jul; 374(9684):126-35. PubMed ID: 19515415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The dual PPARα/γ agonist aleglitazar increases the number and function of endothelial progenitor cells: implications for vascular function and atherogenesis.
    Werner CM; Schirmer SH; Gensch C; Pavlickova V; Pöss J; Wright MB; Böhm M; Laufs U
    Br J Pharmacol; 2014 May; 171(10):2685-703. PubMed ID: 24467636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
    Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M
    J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The mechanisms of carnosic acid attenuates tumor necrosis factor-α-mediated inflammation and insulin resistance in 3T3-L1 adipocytes.
    Tsai CW; Liu KL; Lin YR; Kuo WC
    Mol Nutr Food Res; 2014 Apr; 58(4):654-64. PubMed ID: 24668853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
    Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of PPARalpha activation of macrophages on the secretion of inflammatory cytokines in cultured adipocytes.
    Murakami K; Bujo H; Unoki H; Saito Y
    Eur J Pharmacol; 2007 Apr; 561(1-3):206-13. PubMed ID: 17320860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of MHY908, a New Synthetic PPARα/γ Dual Agonist, on Inflammatory Responses and Insulin Resistance in Aged Rats.
    Park MH; Kim DH; Kim MJ; Lee EK; An HJ; Jeong JW; Kim HR; Kim SJ; Yu BP; Moon HR; Chung HY
    J Gerontol A Biol Sci Med Sci; 2016 Mar; 71(3):300-9. PubMed ID: 26219845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aleglitazar, a Balanced Dual PPARα and -γ Agonist, Protects the Heart Against Ischemia-Reperfusion Injury.
    Qian J; Chen H; Birnbaum Y; Nanhwan MK; Bajaj M; Ye Y
    Cardiovasc Drugs Ther; 2016 Apr; 30(2):129-41. PubMed ID: 26861490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. c-Jun N-terminal kinase 1/2 activation by tumor necrosis factor-alpha induces insulin resistance in human visceral but not subcutaneous adipocytes: reversal by liver X receptor agonists.
    Fernández-Veledo S; Vila-Bedmar R; Nieto-Vazquez I; Lorenzo M
    J Clin Endocrinol Metab; 2009 Sep; 94(9):3583-93. PubMed ID: 19567513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipolytic and antiadipogenic effects of (3,3-dimethylallyl) halfordinol on 3T3-L1 adipocytes and high fat and fructose diet induced obese C57/BL6J mice.
    Saravanan M; Pandikumar P; Saravanan S; Toppo E; Pazhanivel N; Ignacimuthu S
    Eur J Pharmacol; 2014 Oct; 740():714-21. PubMed ID: 24952133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peroxisome proliferator-activated receptor activity is involved in the osteoblastic differentiation regulated by bone morphogenetic proteins and tumor necrosis factor-α.
    Takano M; Otsuka F; Matsumoto Y; Inagaki K; Takeda M; Nakamura E; Tsukamoto N; Miyoshi T; Sada KE; Makino H
    Mol Cell Endocrinol; 2012 Jan; 348(1):224-32. PubMed ID: 21888945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical mechanism of insulin sensitization, lipid modulation and anti-atherogenic potential of PPAR alpha/gamma dual agonist: Ragaglitazar.
    Sharma S; Sowjanya A; Kumari M; Suryaprakash R; Cynthia G; Suresh J; Chakrabarti R
    Life Sci; 2006 Dec; 80(3):235-44. PubMed ID: 17014868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. P633H, a novel dual agonist at peroxisome proliferator-activated receptors alpha and gamma, with different anti-diabetic effects in db/db and KK-Ay mice.
    Chen W; Zhou XB; Liu HY; Xu C; Wang LL; Li S
    Br J Pharmacol; 2009 Jul; 157(5):724-35. PubMed ID: 19422369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Additive regulation of adiponectin expression by the mediterranean diet olive oil components oleic Acid and hydroxytyrosol in human adipocytes.
    Scoditti E; Massaro M; Carluccio MA; Pellegrino M; Wabitsch M; Calabriso N; Storelli C; De Caterina R
    PLoS One; 2015; 10(6):e0128218. PubMed ID: 26030149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
    Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R
    Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel dual peroxisome proliferator-activated receptors alpha and gamma agonist with beneficial effects on insulin resistance and lipid metabolism.
    Xu C; Wang LL; Liu HY; Ruan CM; Zhou XB; Cao YL; Li S
    Biotechnol Lett; 2006 Jun; 28(12):863-8. PubMed ID: 16786270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
    Ruilope L; Hanefeld M; Lincoff AM; Viberti G; Meyer-Reigner S; Mudie N; Wieczorek Kirk D; Malmberg K; Herz M
    BMC Nephrol; 2014 Nov; 15():180. PubMed ID: 25407798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.